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Background: Mutations in the gene STUB1, encoding the protein CHIP (C-terminus of HSC70-interacting protein),
have recently been suggested as a cause of recessive ataxia based on the findings in few Chinese families. Here we
aimed to investigate the phenotypic and genotypic spectrum of STUB1 mutations, and to assess their frequency in
different Caucasian disease cohorts.
Methods: 300 subjects with degenerative ataxia (n = 167) or spastic paraplegia (n = 133) were screened for STUB1
variants by whole-exome-sequencing (n = 204) or shotgun-fragment-library-sequencing (n = 96). To control for
the specificity of STUB1 variants, we screened an additional 1707 exomes from 891 index families with other
neurological diseases.
Results: We identified 3 ataxia patients (3/167 = 1.8%) with 4 novel missense mutations in STUB1, including 3 mutations
in its tetratricopeptide-repeat domain. All patients showed evidence of pyramidal tract damage. Cognitive impairment
was present only in one and hypogonadism in none of them. Ataxia did not start before age 48 years in one subject. No
recessive STUB1 variants were identified in families with other neurological diseases, demonstrating that STUB1 variants
are not simply rare polymorphisms ubiquitous in neurodegenerative disease.
Conclusions: STUB1-disease occurs also in Caucasian ataxia populations (1.8%). Our results expand the genotypic
spectrum of STUB1-disease, showing that pathogenic mutations affect also the tetratricopeptide-repeat domain, thus
providing clinical evidence for the functional importance of this domain. Moreover, they further delineate the phenotypic
core features of STUB1-ataxia. Pyramidal tract damage is a common accompanying feature and can include lower limb
spasticity, thus adding STUB1-ataxia to the differential diagnosis of “spastic ataxias”. However, STUB1 is rare in subjects
with predominant spastic paraplegia (0/133). In contrast to previous reports, STUB1-ataxia can start even above age
40 years, and neither hypogonadism nor prominent cognitive impairment are obligatory features.
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Whole exome-sequencing (WES) has led to the identifica-
tion of many novel candidates genes for recessive ataxias. If
confirmed in additional families and independent cohorts,
these findings allow for a molecular diagnosis in the still
large amount of patients with hitherto undefined recessive
ataxia syndromes and for a delineation of phenotypic
spectra in this highly heterogeneous group of diseases
unified by common genetic causes [1,2]. For example,
missense mutations in STUB1 encoding the protein
CHIP (C-terminus of HSC70-interacting protein), which
functions as a molecular co-chaperone and ubiquitin E3
ligase and which interacts with several proteins involved
in degenerative ataxia disease [3], have recently been
suggested as a cause of early-onset recessive ataxia
with hypogonadism [4,5]. This finding was supported by
animal studies, but information about the core symptoms
and the phenotypic and mutational spectrum is limited, as
only very few families with STUB1 mutations have
been reported so far [4,5]. Moreover, the frequency in
Caucasian disease populations is unknown, as STUB1
has been reported only from Chinese subjects.
Using two large-scale screening approaches we here iden-
tified 3 novel STUB1 families. These findings demonstrate
that STUB1-ataxia occurs also in Caucasian populations.
Moreover, they help to delineate the phenotypic core
features and to expand the genetic spectrum. We show that
STUB1 mutations are frequently associated with pyramidal
tract damage, including lower limb spasticity. However, in
contrast to the first report of STUB1-ataxia [4], neither
hypogonadism nor prominent cognitive impairment
are core symptoms of the disease. Finally, our find-
ings show that pathogenic mutations affect also the
tetratricopeptide-repeat domain of STUB1, thus comple-
menting experimental findings about the substantial
functional importance of this domain.
Methods
WES of ataxia and spastic paraplegia subjects
N = 71 subjects with early-onset degenerative ataxia
(age of onset <30 years) compatible with autosomal
recessive inheritance (no ataxia in the parental generation),
negative for trinucelotide repeat expansions causing
Friedreich’s ataxia (FRDA) and spinoncerebellar ataxia
(SCA) type 1, 2, 3, 6, 7, and 17, underwent whole
exome-sequencing. Given the fact that pyramidal tract
damage to the upper and lower limb was observed in
the first reported STUB1 family [4], we additionally
exome-sequenced n = 133 subjects with pure or compli-
cated hereditary spastic paraplegia (HSP), each compatible
with autosomal recessive disease. WES was perfomed
using the SureSelect Human All Exon 50 Mb kit (Agilent,
Santa Clara, CA, USA) for in-solution enrichment
and the Hiseq2000 instrument (Illumina, San Diego,CA, USA) as described previously ([6]; for details, see
Additional file 1).
Shotgun fragment library sequencing in ataxia subjects.
N = 96 additional subjects with early-onset degenerative
ataxia (age of onset <30 years) negative for SCA 1,2,3,6,7,17
and FRDA repeats were sequenced for STUB1 variants
by shotgun fragment library sequencing by a Nextera
approach (Illumina, San Diego, CA, USA). Briefly, the
complete locus of the STUB1 gene (2,654 bp including 5
prime and 3 prime untranslated region) was amplified
in a single 3 kb PCR fragment and subjected to transposon-
based library generation using the Nextera-XT chemistry
with molecular identifiers (MID) according the manufac-
turer’s protocol. MID barcoded libraries were pooled and
short fragments were removed before a pool of 96 samples
was sequenced using Illumina MiSeq V2 chemistry
with 2× 150 bp paired-end reads (Illumina, San Diego,
CA, USA). After quality filtering, mapping and annotation
was done with standard tools and public databases (hg19,
stampy, dbSNP134, EVS, annovar). For all samples, the
complete STUB1 locus was covered >100 reads.
Exclusion of additional mutations in known ataxia
genes by high-coverage targeted enrichment (“ataxia
panel”). The ataxia syndrome in patients identified to
carry two STUB1 variants by shotgun sequencing might
be alternatively explained by an additional mutation in
another ataxia gene. To reduce this likelihood, the STUB1
patient identified by shotgun sequencing (subject 91078)
was additionally screened for mutations in >120 known
ataxia genes by a high coverage (>94% mean coverage)
HaloPlex gene panel kit (Agilent, Santa Clara, CA, USA;
details in Additional file 2).
STUB1 seed analysis in >1700 exomes of other neuro-
logical diseases. To assess the general genetic variability of
the STUB1 gene unrelated to ataxia or spastic paraplegia,
we screened STUB1 mutations in n = 1707 additional
exomes from 891 families with a wide range of other
(i.e. non-ataxia, non-HSP) neurological phenotypes
including e.g. Charcot-Marie-Tooth disease, amyotrophic
lateral sclerosis, Alzheimer’s disease and others using re-
laxed filter conditions (MAF EVS6500 < 3%, QUAL > 30,
GQ > 30, < 10 additional families in the in-house database
GEM.app with the same segregating variant) [7].
Ethics approval
This study was carried out in compliance with the
Helsinki Declaration, and approved by the Institutional




We identified 3 ataxia index patients with either homozygous
mutations (c.367C >G, p.Leu123Val and c.719 T >C,
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or compound heterozygous mutations (c.235G > A;
c.236C > A, p.Ala79Thr; p.Ala79Asp in one patient with
non- consanguineous parents) in the STUB1 gene (tran-
script NM_005861). The 3 index families came from
Germany, western Turkey, and Saudi Arabia, respectively.
All 4 novel STUB1 variants identified in these cases affect
highly conserved amino acid residues, are predicted to be
damaging by at least three in silico prediction algorithms,
and were neither found in > 2,500 additional exomes of
the Gem.app database (including 200 individuals of
Turkish/Arab origin) [7] nor in the 6,500 exomes of
the NHLBI Exome Variant Server (EVS) (NHLBI GO
Exome Sequencing Project [ESP], Seattle, WA; URL:
http://evs.gs.washington.edu/EVS/, accessed January
2014) (Table 1). All mutations were confirmed by Sanger
sequencing (for electropherograms, see Additional file 3).
The variants cosegregated with disease where affected
siblings were available (family #3), and were present only
in a heterozygous state in unaffected siblings (family #1)
(Figure 1A). For two of the three families we were
able to confirm localization of the variants in trans.
In family #1 this was achieved by sequencing of the
parents (Additional file 3), in family #3 manual
inspection of the sequencing reads established compound
heterozygosity (Additional file 4). No other significant
variants in known ataxia genes were identified in any
of the three index subjects by WES and HaloPlex
panel, respectively (for a list of the remaining gene
variants after filtering, see Additional file 5).
While the p.Met240Thr variant is located in the
U-box domain of CHIP, close to the previously described
Thr246Met variant [4], the p.Leu123Val, p.Ala79Thr and
Ala79Asp variants are located in the tetratricopeptide-
repeat (TPR) domain (Figure 1B).
The three STUB1 index patients account for 3/167 = 1.8%
of all ataxia patients in our cohort. No STUB1 variants
were found in HSP patients (0/133 = 0%). Screening
of STUB1 variants in 1707 additional whole exomes from
families with other neurological phenotypes revealed 6
heterozygous STUB1 variants (Additional file 6), but no
other homozygous or compound heterozygous variants.Table 1 STUB1 mutations identified in this study
Subject ID Phenotype cDNA change Protein
change
18161 Ataxia with pyramidal
damage
c.367C > G, c.367C > G p.Leu123Val
91078 Ataxia with pyramidal
damage
c.719 T > C, c.719 T > C p.Met240Thr
25130_01 Spastic ataxia c.235G > A, p.Ala79Thr
c.236C > A p.Ala79Asp
GVS, Genome Variant Server; GERP, Genomic Evolutionary Rate Profiling; LRT, Likelih
NHLBI exome variant server; Gem.app MAF, Minor allele frequency in the in-house dThis demonstrates that the recessive STUB1 mutations
observed in our target cohort are not simply rare poly-
morphisms ubiquitous in neurodegenerative disease.
Phenotypic findings
All three index patients carrying two recessive STUB1
mutations presented with cerebellar ataxia as the main
and initial feature (for clinical details, see Table 2). Age
of onset was highly variable, extending from age 2 years
in subject 91078 to age 48 years in the brother of patient
25130_10. Evidence for pyramidal tract damage was
found in all 4 patients. Two of them (25130_01 and his
brother), showed clinical signs of pyramidal tract
damage (increased lower limb tendon reflexes, non-
exhaustible ankle clonus, mild lower limb spasticity) with
normal central motor conduction times (CMCTs), while
the other two subjects (91078 and 18161) displayed
electrophysiological evidence of pyramidal tract
damage with prolonged CMCTs. Subject 91078 showed
myoclonic jerks in the face and the left arm. Distribution
and phenomenology of the myoclonus point to a cortical
origin, however no EMG-EEG recordings were avail-
able to confirm this hypothesis. Furthermore, subject
91078 had a mildly reduced vibration sense to the
legs, which corresponded with electrophysiological
evidence of sensory axonal peripheral neuropathy. No
hypogonadism was clinically observed in any of the
patients, and hormone investigations (available for 3/3
index patients) and testicular sonography findings
(available for patient 18161) were normal. Whereas
subject 91078 showed clinical signs of concentration
difficulties, corresponding to mild deficits in working
memory span (digit span and block span) and execu-
tive attention (Trail Making Test part B) on neuro-
psychological testing, no cognitive impairment was
clinically observable in subjects 18161 and 25130_01.
Neuropsychological testing by means of the German
version of the Wechsler Intelligence Scale for Chil-
dren [8] was normal in subject 18161. All patients
showed marked cerebellar atrophy on MRI, subject
18161 presented also mild parietal cortical atrophy
(Figure 2).GVS
function






Missense 3,6 1 D D 0 0
Missense 4,3 0.99 D D 0 0
Missense 4.3 0,996 D D 0 0
Missense 4.3 0.996 D D 0 0
ood Ratio Test; D, Damaging; NHLBI EVS MAF, Minor allele frequency in the
atabase Gem.app.
Figure 1 Pedigrees of STUB1 index patients, and location and conservation of STUB 1 mutations. (A) Pedigrees of families #1 and 2 reveal
consanguinity with parents being first degree cousins. Family #3 shows two affected siblings. (B) The protein structure shows that the p.
Met240Thr variant is located in the U-box domain of CHIP, whereas the p.Leu123Val, p.Ala79Thr and Ala79Asp variants are located in the
tetratricopeptide-repeat (TPR) domain. All variants are highly conserved across species.
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Recessive mutations in STUB1 have recently been sug-
gested as a cause of recessive ataxia [4,5], but knowledge
about the phenotypic and genotypic spectrum is limited
and no mutations have been reported in non-Chinese
populations so far. Here we show that STUB1-ataxia
is not limited to Chinese populations, but can be ob-
served also in Caucasian ataxia patients (frequency:
1.8% of non-Friedreich recessive ataxias). Like in the pre-
viously reported Chinese STUB1 patients [4,5], there
was no obvious preference for female or male gender.
Our findings extend the genotypic and phenotypic
spectrum of STUB1. The mutational spectrum is not
limited to the U-box domain and its adjacent regions
[4,5], but can include also the TPR domain, as we show
for three mutations. This clinico-genetic finding comple-
ments recent experimental investigations demonstrating
that not only the U-box, but also the TPR domain is
crucial for adequate functioning of CHIP in the endo-
plasmatic reticulum protein quality control [11] and for
mediating its interactions with chaperones [12].Our findings show that - in contrast to the first report
of STUB1-ataxia [4] (the second report provides no
comment on the presence or absence of hypogonadism
[5]) - hypogonadism is not an obligate core features of
the disease. Likewise, also cognitive impairment is
more infrequent than suggested by the initial report [4].
These findings are in line with other recently identified
multisystemic recessive ataxias which extend along a
continuous phenotypic spectrum and where hypogonadism
or cognitive impairment are only variable and infrequent
features (see e.g. PNPLA6 ataxia [6]).
In contrast to hypogonadism and cognitive impairment,
pyramidal tract damage seems to be a more common
feature of STUB1-ataxia. It is present in all three of our
families (clinically in patient 25130_01 and his brother;
electrophysiologically in the other two index patients). The
difference between clinical and electrophysiological findings
of pyramidal tract damage in these patients does not
necessarily indicate an inconsistency. Electrophysiological
evidence of pyramidal damage in the absence of clinical
pyramidal tract signs (as observed in 91078 and 18161)
Table 2 Clinical, MRI and lab findings of STUB1 mutation carriers














18161 p.Leu123Val M 16 2 Normal - - - + - -
91078 p.Met240Thr F 21 16 Normal - - - + - +
25130_01 p.Ala79Thr; Ala79Asp M 46 29 Increased Lower limb, mild - + bilateral - - -
25130_10 .p.Ala79Thr; Ala79Asp M 50 49 Increased Lower limb. moderate - + bilateral + - -
Subject SDFS SARA SPRS Nerve conduction studies Motor evoked
potentials
MRI Hormones Testicular volume
(sonography)Sensory Motor
18161 3 10 n.a. Sural nerve: normal Tibial nerve:
normal
Prolonged CMCT
to LE (18 ms)
Atrophy cerebellum
and parietal cortex
Testosteron normal (236 ng/dl) 25 ml, each side
Estradiol normal (8,4 pg/ml
LH normal (3,6 IU/l)
FSH normal (0,7 IU/l)




Prolonged CMCT to UE
(10 ms), not evoked to LE
Atrophy cerebellum Estradiol normal (50 pg/ml) n.a.
LH normal (8.3 mE/ml)
FSH normal (3.7 mE/ml)
25130_01 6 n.d. 38 n.d. n.d. Normal Atrophy cerebellum Testosteron (4.3 ng/ml) n.d.
Estradiol normal (22 pg/ml9
LH normal (9.6 mU/l)
FSH normal (16.0 mU/ml)
25130_10 3 14.5 5 n.d. n.d. Normal Atrophy cerebellum n.d. n.d.
Legend: m, male; f, female; n.a., not applicable, n.d., not done; SARA, scale for the Assessment and Rating of Ataxia, reaching from 0 to 40, with higher scores indicating more severe ataxia [9]; scores < 3 points are
considered unspecific. SPRS, spastic paraplegia rating scale, reaching from 0 to 52, with higher scores indicating more severe spastic paraplegia [10] (please note, however, that several items of the SPRS scale increase
also with more severe ataxia); CMCT: Central motor conduction time. Reference values CMCT lower extremity (LE) < 16.0 ms; CMCT upper extremity (UE) < 9 ms. LE, lower extremity; UE, upper extremity; LH, luteinizing
hormone; FSH, follicle-stimulating hormone; SNAP, sensory nerve action potential; MRI, magnetic resonance imaging. SDFS, Spinocerebellar degeneration functional score. This score was used to evaluate the disability
stage from 1 to 7 (0: no functional handicap; 1: no functional handicap but signs at examination; 2: mild, able to run, walking unlimited; 3: moderate, unable to run, limited walking without help; 4: severe, walking with



















Figure 2 Cerebral Magnetic Resonance Imaging in STUB1 ataxia. T2 (A: sagittal; B, coronal; C, sagittal) and T1 weighted images (D, axial) of
subject 18161 at age 17 years show marked atrophy of the cerebellar vermis (arrow, A) as well as the cerebellar hemispheres (arrows, B), and mild
atrophy of the parietal cortex (arrows C, D).
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pyramidal tract signs in the absence of electrophysiogical
evidence of pyramidal damage (as observed in 25130_01
and his brother) is a feature commonly seen in hereditary
spastic paraplegias [13], and most likely explained by
predominantly axonal damage of the corticospinal
tracts in these subjects [13]. Pyramidal tract signs were
also observed in several of the previously reported STUB1
families [4,5]. In sum, this frequent combination of ataxia
with pyramidal tract damage indicates that STUB1 ataxia
should be added to the differential diagnosis of
the rapidly increasing list of “spastic ataxia” spectrum
disorders [14].
The clinical/electrophysiological observation of frequent
pyramidal tract damage in STUB1 also provides an
important insight into the underlying pathophysiology:
mutant CHIP seems to lead to a dysfunction not only
of cerebellar neurons, but also of motor neurons. This
clinical observation complements and corroborates
findings from several molecular studies which indicate
that CHIP acts as a common central hub in different
pathways of a large variety of neurodegenerative
diseases, including motor neuron diseases [15]. Acting
as co-chaperone and ubiquitin ligase, CHIP is acentral component of neuronal protein homeostasis
[16]. It forms a multiheteromeric complex with other
chaperons, which together selectively activate autoph-
agic removal and degradation of misfolded proteins
[17]. Apart from key ataxia proteins like ataxin-1 [12]
or ataxin-3 [3,16], this degradation also includes
proteins involved in motor neuron disease such as
SOD1 proteins [17-19]. Thus, mutations in STUB1/
CHIP, as observed in our patients, might lead to an
impaired clearance of naturally occuring misfolded
motor neuron proteins. This hypothesis stimulates
future functional and pathology studies required to
confirm this notion.
From clinical perspective it is interesting to note, however,
that albeit upper motor neuron damage is common in
STUB1 disease, spastic paraparesis does not seem to be a
predominant phenotype. This as indicated by the absence
of STUB1mutations in our large HSP cohort.
Conclusions
Our results show for the first time that STUB1 ataxia oc-
curs also outside of Chinese populations (frequency 1.8%
of non-Friedreich recessive ataxias), and expand the muta-
tional spectrum of this disease. They demonstrate a
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neuron damage in STUB1-disease. At the same time,
however, they show that STUB1 is not observed in
HSP patients. In contrast to the initial notion of
STUB1-disease, hypogonadism seems to be an only
infrequent feature of this disease.
Additional files
Additional file 1: Whole exome sequencing methods.
Additional file 2: Targeted enrichment of known ataxia genes
(“ataxia panel”).
Additional file 3: Electropherograms of Sanger Sequencing.
Additional file 4: Sequencing Reads of an affected family member
of family #3.
Additional file 5: Genetic variants other than STUB1 identified in
the STUB1 index patients by whole exome sequencing and the
HaloPlex ataxia panel.
Additional file 6: Heterozygous variants in STUB1 identified in a
cohort of 1707 neurological disease controls (non-ataxia, non-HSP).
Abbreviations
ARCA: Autosomal recessive cerebellar ataxia; HSP: Hereditary spastic
paraplegia; WES: Whole exome sequencing; TPR: Tetratricopeptide-repeat.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MS: design and conceptualization of the study, acquisition of data, analysis
of the data, drafting the manuscript. RS: conceptualization of the study,
acquisition of data, analysis of the data, revising the manuscript. MS, JG-A, RS,
AS, IK-M, MG, PY, SZ, LS: acquisition of data, analysis and interpretation of the
data, revising the manuscript. PB: design and conceptualization of the study,
acquisition of data; analysis and interpretation of the data, revising the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We are grateful to Jennifer Reichbauer (Hertie-Institute for Clinical Brain
Research, Tübingen) and Avencia Sanchez Mejias Garcia (John P. Hussman
Institute for Human Genomics, Miami) for performing the Sanger sequencing
in some of the subjects. This study was supported by the Interdisciplinary
Center for Clinical Research IZKF Tübingen (grant 2191-0-0 to MS, grant
1970-0-0 to RS), the European Union (grant F5-2012-305121 “NEUROMICS” to
LS and grant PIOF-GA-2012-326681 “HSP/CMT genetics” to RS), E-RARE grants
of the German Ministry for Education and Research (BMBF) to the EUROSCAR
project (grant 01GM1206) and the EUROSPA project (grant 01GM0807) (to LS
and PB), and the National Institute of Health (NIH) (grants 5R01NS072248 to
SZ, 1R01NS075764 to SZ, 5R01NS054132 to SZ). We acknowledge support by
the “Deutsche Forschungsgemeinschaft” (DFG) and the Open Access Publishing
Fund of Tuebingen University.
Author details
1Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain
Research, University of Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen,
Germany. 2German Research Center for Neurodegenerative Diseases (DZNE),
University of Tübingen, Tübingen, Germany. 3Dr. John T. Macdonald
Foundation Department of Human Genetics and John P. Hussman Institute
for Human Genomics, University of Miami Miller School of Medicine, Miami,
USA. 4Institute of Medical Genetics and Applied Genomics, University of
Tübingen, Tübingen, Germany. 5Department of Neuropediatrics, University of
Tübingen, Tübingen, Germany. 6Department of General Pedatrics, Pediatric
Endocrinology and Diabetology, University of Tübingen, Tübingen, Germany.
7Department of Sleep Medicine and Neuromuscular Disorders, Neurology,
University Hospital Münster, Münster, Germany.Received: 18 February 2014 Accepted: 11 April 2014
Published: 17 April 2014References
1. Anheim M, Tranchant C, Koenig M: The autosomal recessive cerebellar
ataxias. N Engl J Med 2012, 366:636–646.
2. Synofzik M, Schöls L, Rieß O: Hereditäre Ataxien: Aktuelle Übersicht und
diagnostische Strategien Medizinische Genetik; 2013:235–248.
3. Jana NR, Dikshit P, Goswami A, Kotliarova S, Murata S, Tanaka K, Nukina N:
Co-chaperone CHIP associates with expanded polyglutamine protein
and promotes their degradation by proteasomes. J Biol Chem 2005,
280:11635–11640.
4. Shi CH, Schisler JC, Rubel CE, Tan S, Song B, McDonough H, Xu L,
Portbury AL, Mao CY, True C, Wang RH, Wang QZ, Sun SL, Seminara SB,
Patterson C, Xu YM: Ataxia and hypogonadism caused by the loss of
ubiquitin ligase activity of the U box protein CHIP. Hum Mol Genet 2014,
23:1013–1024.
5. Shi Y, Wang J, Li JD, Ren H, Guan W, He M, Yan W, Zhou Y, Hu Z, Zhang J,
Xiao J, Su Z, Dai M, Wang J, Jiang H, Guo J, Zhou Y, Zhang F, Li N, Du J,
Xu Q, Hu Y, Pan Q, Shen L, Wang G, Xia K, Zhang Z, Tang B: Identification
of CHIP as a novel causative gene for autosomal recessive cerebellar
ataxia. PLoS One 2013, 8:e81884.
6. Synofzik M, Gonzalez MA, Lourenco CM, Coutelier M, Haack TB, Rebelo A,
Hannequin D, Strom TM, Prokisch H, Kernstock C, Durr A, Schols L,
Lima-Martinez MM, Farooq A, Schule R, Stevanin G, Marques W Jr,
Zuchner S: PNPLA6 mutations cause Boucher-Neuhauser and Gordon
Holmes syndromes as part of a broad neurodegenerative spectrum.
Brain 2014, 137:69–77.
7. Gonzalez MA, Lebrigio RF, van Booven D, Ulloa RH, Powell E, Speziani F,
Tekin M, Schule R, Zuchner S: GEnomes management application
(GEM.app): a new software tool for large-scale collaborative genome
analysis. Hum Mutat 2013, 34:842–846.
8. Petermann F, Petermann U: HAWIK-IV (3. erweiterte Aufl.). Bern: Huber; 2010.
9. Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C,
Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B,
Pandolfo M, Rakowicz M, Ribai P, Rola R, Schols L, Szymanski S,
van de Warrenburg BP, Durr A, Klockgether T, Fancellu R: Scale for
the assessment and rating of ataxia: development of a new clinical
scale. Neurology 2006, 66:1717–1720.
10. Schule R, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V, Otto S,
Winner B, Schols L: The Spastic Paraplegia Rating Scale (SPRS): a
reliable and valid measure of disease severity. Neurology 2006,
67:430–434.
11. Matsumura Y, Sakai J, Skach WR: Endoplasmic reticulum protein
quality control is determined by cooperative interactions between
Hsp/c70 protein and the CHIP E3 ligase. J Biol Chem 2013,
288:31069–31079.
12. Al-Ramahi I, Lam YC, Chen HK, de Gouyon B, Zhang M, Perez AM,
Branco J, de Haro M, Patterson C, Zoghbi HY, Botas J: CHIP protects
from the neurotoxicity of expanded and wild-type ataxin-1 and
promotes their ubiquitination and degradation. J Biol Chem 2006,
281:26714–26724.
13. Karle KN, Schule R, Klebe S, Otto S, Frischholz C, Liepelt-Scarfone I, Schols L:
Electrophysiological characterisation of motor and sensory tracts in
patients with hereditary spastic paraplegia (HSP). Orphanet J Rare Dis
2013, 8:158.
14. de Bot ST, Willemsen MA, Vermeer S, Kremer HP, van de Warrenburg BP:
Reviewing the genetic causes of spastic-ataxias. Neurology 2012,
79:1507–1514.
15. Sha Y, Pandit L, Zeng S, Eissa NT: A critical role for CHIP in the aggresome
pathway. Mol Cell Biol 2009, 29:116–128.
16. Williams AJ, Knutson TM, Colomer Gould VF, Paulson HL: In vivo
suppression of polyglutamine neurotoxicity by C-terminus of
Hsp70-interacting protein (CHIP) supports an aggregation model of
pathogenesis. Neurobiol Dis 2009, 33:342–353.
17. Crippa V, Sau D, Rusmini P, Boncoraglio A, Onesto E, Bolzoni E, Galbiati M,
Fontana E, Marino M, Carra S, Bendotti C, De Biasi S, Poletti A: The small
heat shock protein B8 (HspB8) promotes autophagic removal of
misfolded proteins involved in amyotrophic lateral sclerosis (ALS).
Hum Mol Genet 2010, 19:3440–3456.
Synofzik et al. Orphanet Journal of Rare Diseases 2014, 9:57 Page 8 of 8
http://www.ojrd.com/content/9/1/5718. Urushitani M, Kurisu J, Tateno M, Hatakeyama S, Nakayama K, Kato S,
Takahashi R: CHIP promotes proteasomal degradation of familial
ALS-linked mutant SOD1 by ubiquitinating Hsp/Hsc70. J Neurochem
2004, 90:231–244.
19. Ishigaki S, Niwa J, Yamada S, Takahashi M, Ito T, Sone J, Doyu M, Urano F,
Sobue G: Dorfin-CHIP chimeric proteins potently ubiquitylate and
degrade familial ALS-related mutant SOD1 proteins and reduce their
cellular toxicity. Neurobiol Dis 2007, 25:331–341.
doi:10.1186/1750-1172-9-57
Cite this article as: Synofzik et al.: Phenotype and frequency of STUB1
mutations: next-generation screenings in Caucasian ataxia and spastic
paraplegia cohorts. Orphanet Journal of Rare Diseases 2014 9:57.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
